USP22 and lung adenocarcinoma: In lung adenocarcinoma, USP22 inhibition decreases ALDH1A3 expression, heightens the sensitivity of tumor cells to cisplatin, particularly CD133+ cancer-initiating cells, and attenuates their stem cell-like properties [61].